Oxidized phospholipids on Lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans

Circulation

Volumn 134, Issue 8, 2016, Pages 611-624

  Van Der Valk, Fleur M ^a   Bekkering, Siroon ^c   Kroon, Jeffrey ^b   Yeang, Calvin ^d   Van Den Bossche, Jan ^b   Van Buul, Jaap D ^a   Ravandi, Amir ^e   Nederveen, Aart J ^a   Verberne, Hein J ^a   Scipione, Corey ^f   Nieuwdorp, Max ^a   Joosten, Leo A B ^c   Netea, Mihai G ^c   Koschinsky, Marlys L ^g   Witztum, Joseph L ^d   Tsimikas, Sotirios ^d   Riksen, Niels P ^c   Stroes, Erik S G ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b SANQUIN RESEARCH   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF MANITOBA   (Canada)

^f UNIVERSITY OF WINDSOR   (Canada)

^g ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

atherosclerosis; lipoproteins; monocytes

Indexed keywords

C REACTIVE PROTEIN; CD163 ANTIGEN; CD200 RECEPTOR; CD36 ANTIGEN; CHOLESTEROL; FLUORODEOXYGLUCOSE F 18; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; L SELECTIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPID; TOLL LIKE RECEPTOR 2; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; AUTACOID;

ADULT; ARTERIAL WALL INFLAMMATION; ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CELL ISOLATION; CELLULAR IMMUNITY; CEREBRAL ARTERY DISEASE; CLINICAL ARTICLE; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CYTOKINE PRODUCTION; EX VIVO STUDY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LIPOPROTEIN BLOOD LEVEL; MALE; MIDDLE AGED; MONOCYTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; AGED; AORTA; CELL CULTURE; CELL MOTION; CLINICAL TRIAL; DIAGNOSTIC IMAGING; METABOLISM; MONONUCLEAR CELL; PHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY;

ADULT; AGED; AORTA; CELL MOVEMENT; CELLS, CULTURED; FEMALE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LEUKOCYTES, MONONUCLEAR; LIPOPROTEIN(A); MALE; MIDDLE AGED; PHOSPHOLIPIDS; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY;

EID: 84981276527     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.116.020838     Document Type: Article

References (54)

1. Kronenberg F, Utermann G. Lipoprotein(a): resurrected by genetics. J Intern Med. 2013; 273: 6-30. doi: 10.1111/j.1365-2796.2012.02592.x
2. Thanassoulis G. Lipoprotein(a) in calcific aortic valve disease: from genomics to novel drug target for aortic stenosis. J Lipid Res. 2016; 57: 917-924. doi: 10.1194/jlr.R051870
3. Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, Ginsberg H, Amarenco P, Catapano A, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Reiner Z, Taskinen MR, Tokgözoglu L, Tybjarg-Hansen A; European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010; 31: 2844-2853. doi: 10.1093/eurheartj/ehq386
4. Tsimikas S, Hall JL. Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. J Am Coll Cardiol. 2012; 60: 716-721. doi: 10.1016/j. jacc.2012.04.038
5. Tabas I, Williams KJ, Borén J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation. 2007; 116: 1832-1844. doi: 10.1161/CIRCULATIONAHA.106.676890
6. Dubé JB, Boffa MB, Hegele RA, Koschinsky ML. Lipoprotein(a): more interesting than ever after 50 years. Curr Opin Lipidol. 2012; 23: 133-140. doi: 10.1097/MOL.0b013e32835111d8
7. Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS, Witztum JL, Berger PB. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med. 2005; 353: 46-57. doi: 10.1056/NEJMoa043175
8. Bergmark C, Dewan A, Orsoni A, Merki E, Miller ER, Shin MJ, Binder CJ, Hörkkö S, Krauss RM, Chapman MJ, Witztum JL, Tsimikas S. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res. 2008; 49: 2230-2239. doi: 10.1194/jlr.M800174-JLR200
9. Leibundgut G, Scipione C, Yin H, Schneider M, Boffa MB, Green S, Yang X, Dennis E, Witztum JL, Koschinsky ML, Tsimikas S. Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a). J Lipid Res. 2013; 54: 2815-2830. doi: 10.1194/jlr.M040733
10. Tsimikas S, Witztum JL. The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity. Curr Opin Lipidol. 2008; 19: 369-377. doi: 10.1097/MOL.0b013e328308b622
11. Lee S, Birukov KG, Romanoski CE, Springstead JR, Lusis AJ, Berliner JA. Role of phospholipid oxidation products in atherosclerosis. Circ Res. 2012; 111: 778-799. doi: 10.1161/CIRCRESAHA. 111.256859
12. Miller YI, Choi SH, Wiesner P, Fang L, Harkewicz R, Hartvigsen K, Boullier A, Gonen A, Diehl CJ, Que X, Montano E, Shaw PX, Tsimikas S, Binder CJ, Witztum JL. Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ Res. 2011; 108: 235-248. doi: 10.1161/CIRCRESAHA.110.223875
13. Leibundgut G, Witztum JL, Tsimikas S. Oxidation-specific epitopes and immunological responses: translational biotheranostic implications for atherosclerosis. Curr Opin Pharmacol. 2013; 13: 168-179. doi: 10.1016/j.coph.2013.02.005
14. Taleb A, Witztum JL, Tsimikas S. Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events. Biomark Med. 2011; 5: 673-694. doi: 10.2217/bmm.11.60
15. Tsimikas S, Willeit P, Willeit J, Santer P, Mayr M, Xu Q, Mayr A, Witztum JL, Kiechl S. Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events. J Am Coll Cardiol. 2012; 60: 2218-2229. doi: 10.1016/j.jacc.2012.08.979
16. Tsimikas S, Duff GW, Berger PB, Rogus J, Huttner K, Clopton P, Brilakis E, Kornman KS, Witztum JL. Pro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a). J Am Coll Cardiol. 2014; 63: 1724-1734. doi: 10.1016/j.jacc.2013.12.030
17. Seman LJ, Jenner JL, McNamara JR, Schaefer EJ. Quantification of lipoprotein (a) plasma fraction in plasma and cholesterol in lectin-bound plasma fraction. Clin Chem. 1994; 40: 400-403
18. Duivenvoorden R, de Groot E, Elsen BM, Laméris JS, Van Der Geest RJ, Stroes ES, Kastelein JJ, Nederveen AJ. In vivo quantification of carotid artery wall dimensions: 3.0-Tesla MRI versus B-mode ultrasound imaging. Circ Cardiovasc Imaging. 2009; 2: 235-242. doi: 10.1161/CIRCIMAGING.108.788059
19. Rudd JH, Myers KS, Bansilal S, Machac J, Rafique A, Farkouh M, Fuster V, Fayad ZA. (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J Am Coll Cardiol. 2007; 50: 892-896. doi: 10.1016/j. jacc.2007.05.024
20. Osiri X. OsiriX Imaging Software. http://www.osirix-viewer.com/. Accessed October 1, 2016
21. Van Der Valk FM, Kroon J, Potters WV, Thurlings RM, Bennink RJ, Verberne HJ, Nederveen AJ, Nieuwdorp M, Mulder WJ, Fayad ZA, van Buul JD, Stroes ES. In vivo imaging of enhanced leukocyte accumulation in atherosclerotic lesions in humans. J Am Coll Cardiol. 2014; 64: 1019-1029. doi: 10.1016/j.jacc.2014.06.1171
22. Hirschfeld M, Ma Y, Weis JH, Vogel SN, Weis JJ. Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine toll-like receptor 2. J Immunol. 2000; 165: 618-622
23. Cain WJ, Millar JS, Himebauch AS, Tietge UJ, Maugeais C, Usher D, Rader DJ. Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a]. J Lipid Res. 2005; 46: 2681-2691. doi: 10.1194/jlr.M500249-JLR200
24. Edelstein C, Mandala M, Pfaffinger D, Scanu AM. Determinants of lipoprotein(a) assembly: a study of wild-type and mutant apolipoprotein(a) phenotypes isolated from human and rhesus monkey lipoprotein(a) under mild reductive conditions. Biochemistry. 1995; 34: 16483-16492
25. van Rijssel J, Kroon J, Hoogenboezem M, van Alphen FP, de Jong RJ, Kostadinova E, Geerts D, Hordijk PL, van Buul JD. The Rhoguanine nucleotide exchange factor Trio controls leukocyte transendothelial migration by promoting docking structure formation. Mol Biol Cell. 2012; 23: 2831-2844. doi: 10.1091/mbc.E11-11-0907
26. National Institutes of Health. NIH Image. http://rsb.info.nih.gov/nih-image/
27. Franssen R, Schimmel AW, van Leuven SI, Wolfkamp SC, Stroes ES, Dallinga-Thie GM. In vivo inflammation does not impair ABCA1-mediated cholesterol efflux capacity of HDL. Cholesterol. 2012; 2012: 610741. doi: 10.1155/2012/610741
28. Tarkin JM, Joshi FR, Rudd JH. PET imaging of inflammation in atherosclerosis. Nat Rev Cardiol. 2014; 11: 443-457. doi: 10.1038/nrcardio.2014.80
29. Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell. 2011; 145: 341-355. doi: 10.1016/j.cell.2011.04.005
30. Abeles RD, McPhail MJ, Sowter D, Antoniades CG, Vergis N, Vijay GK, Xystrakis E, Khamri W, Shawcross DL, Ma Y, Wendon JA, Vergani D. CD14, CD16 and HLA-DR reliably identifies human monocytes and their subsets in the context of pathologically reduced HLA-DR expression by CD14(hi)/CD16(neg) monocytes: expansion of CD14(hi)/CD16(pos) and contraction of CD14(lo)/CD16(pos) monocytes in acute liver failure. Cytometry A. 2012; 81: 823-834. doi: 10.1002/cyto.a.22104
31. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005; 5: 953-964. doi: 10.1038/nri1733
32. Cheng SC, Quintin J, Cramer RA, Shepardson KM, Saeed S, Kumar V, Giamarellos-Bourboulis EJ, Martens JH, Rao NA, Aghajanirefah A, Manjeri GR, Li Y, Ifrim DC, Arts RJ, Van Der Veer BM, Van Der Meer BM, Deen PM, Logie C, O'Neill LA, Willems P, van de Veerdonk FL, Van Der Meer JW, Ng A, Joosten LA, Wijmenga C, Stunnenberg HG, Xavier RJ, Netea MG. mTOR-and HIF-1a-mediated aerobic glycolysis as metabolic basis for trained immunity. Science. 2014; 345: 1250684. doi: 10.1126/science.1250684
33. Boullier A, Friedman P, Harkewicz R, Hartvigsen K, Green SR, Almazan F, Dennis EA, Steinberg D, Witztum JL, Quehenberger O. Phosphocholine as a pattern recognition ligand for CD36. J Lipid Res. 2005; 46: 969-976. doi: 10.1194/jlr.M400496-JLR200
34. Friedman P, Horkko S, Steinberg D, Witztum JL, Dennis EA. Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phospholipids: importance of Schiff base formation and aldol condensation. J Biol Chem. 2002; 277: 7010-7020. doi: 10.1074/jbc.M108860200
35. Chang MK, Binder CJ, Miller YI, Subbanagounder G, Silverman GJ, Berliner JA, Witztum JL. Apoptotic cells with oxidation-specific epitopes are immunogenic and proinflammatory. J Exp Med. 2004; 200: 1359-1370. doi: 10.1084/jem.20031763
36. Scipione CA, Sayegh SE, Romagnuolo R, Tsimikas S, Marcovina SM, Boffa MB, Koschinsky ML. Mechanistic insights into Lp(a)-induced IL-8 expression: a role for oxidized phospholipid modification of apo(a). J Lipid Res. 2015; 56: 2273-2285. doi: 10.1194/jlr.M060210
37. Klein JH, Hegele RA, Hackam DG, Koschinsky ML, Huff MW, Spence JD. Lipoprotein(a) is associated differentially with carotid stenosis, occlusion, and total plaque area. Arterioscler Thromb Vasc Biol. 2008; 28: 1851-1856. doi: 10.1161/ATVBAHA.108.169292
38. Guerra R, Yu Z, Marcovina S, Peshock R, Cohen JC, Hobbs HH. Lipoprotein(a) and apolipoprotein(a) isoforms: no association with coronary artery calcification in the Dallas Heart Study. Circulation. 2005; 111: 1471-1479. doi: 10.1161/01. CIR.0000159263.50305.BD
39. Pellegrino M, Furmaniak-Kazmierczak E, LeBlanc JC, Cho T, Cao K, Marcovina SM, Boffa MB, Côté GP, Koschinsky ML. The apolipoprotein(a) component of lipoprotein(a) stimulates actin stress fiber formation and loss of cell-cell contact in cultured endothelial cells. J Biol Chem. 2004; 279: 6526-6533. doi: 10.1074/jbc.M309705200
40. Sotiriou SN, Orlova VV, Al-Fakhri N, Ihanus E, Economopoulou M, Isermann B, Bdeir K, Nawroth PP, Preissner KT, Gahmberg CG, Koschinsky ML, Chavakis T. Lipoprotein(a) in atherosclerotic plaques recruits inflammatory cells through interaction with Mac-1 integrin. FASEB J. 2006; 20: 559-561. doi: 10.1096/fj.05-4857fje
41. Ravandi A, Leibundgut G, Hung MY, Patel M, Hutchins PM, Murphy RC, Prasad A, Mahmud E, Miller YI, Dennis EA, Witztum JL, Tsimikas S. Release and capture of bioactive oxidized phospholipids and oxidized cholesteryl esters during percutaneous coronary and peripheral arterial interventions in humans. J Am Coll Cardiol. 2014; 63: 1961-1971. doi: 10.1016/j.jacc.2014.01.055
42. Shaw PX, Hörkkö S, Chang MK, Curtiss LK, Palinski W, Silverman GJ, Witztum JL. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest. 2000; 105: 1731-1740. doi: 10.1172/JCI8472
43. Gillotte-Taylor K, Boullier A, Witztum JL, Steinberg D, Quehenberger O. Scavenger receptor class B type I as a receptor for oxidized low density lipoprotein. J Lipid Res. 2001; 42: 1474-1482
44. Bird DA, Gillotte KL, Hörkkö S, Friedman P, Dennis EA, Witztum JL, Steinberg D. Receptors for oxidized low-density lipoprotein on elicited mouse peritoneal macrophages can recognize both the modified lipid moieties and the modified protein moieties: implications with respect to macrophage recognition of apoptotic cells. Proc Natl Acad Sci U S A. 1999; 96: 6347-6352
45. Imai Y, Kuba K, Neely GG, Yaghubian-Malhami R, Perkmann T, van Loo G, Ermolaeva M, Veldhuizen R, Leung YH, Wang H, Liu H, Sun Y, Pasparakis M, Kopf M, Mech C, Bavari S, Peiris JS, Slutsky AS, Akira S, Hultqvist M, Holmdahl R, Nicholls J, Jiang C, Binder CJ, Penninger JM. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell. 2008; 133: 235-249. doi: 10.1016/j.cell.2008.02.043
46. Saeed S, Quintin J, Kerstens HH, Rao NA, Aghajanirefah A, Matarese F, Cheng SC, Ratter J, Berentsen K, Van Der Ent MA, Sharifi N, Janssen-Megens EM, Ter Huurne M, Mandoli A, van Schaik T, Ng A, Burden F, Downes K, Frontini M, Kumar V, Giamarellos-Bourboulis EJ, Ouwehand WH, Van Der Meer JW, Joosten LA, Wijmenga C, Martens JH, Xavier RJ, Logie C, Netea MG, Stunnenberg HG. Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity. Science. 2014; 345: 1251086. doi: 10.1126/science.1251086
47. Bekkering S, Quintin J, Joosten L a. B, Van Der Meer JWM, Netea MG, Riksen NP. Oxidized low-density lipoprotein induces longterm proinflammatory cytokine production and foam cell formation via epigenetic reprogramming of monocytes. Arterioscler Thromb Vasc Biol. 2014; 34: 1731-1738. doi: 10.1161/ATVBAHA. 114.303887
48. Byun YS, Lee JH, Arsenault BJ, Yang X, Bao W, DeMicco D, Laskey R, Witztum JL, Tsimikas S; TNT Trial Investigators. Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial. J Am Coll Cardiol. 2015; 65: 1286-1295. doi: 10.1016/j.jacc.2015.01.050
49. Tsimikas S, Viney NJ, Hughes SG, Singleton W, Graham MJ, Baker BF, Burkey JL, Yang Q, Marcovina SM, Geary RS, Crooke RM, Witztum JL. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet. 2015; 386: 1472-1483. doi: 10.1016/S0140-6736(15)61252-1
50. Stroes ES, Van Der Valk FM. A sense of excitement for a specific Lp(a)-lowering therapy. Lancet. 2015; 6736: 23-24
51. Kolski B, Tsimikas S. Emerging therapeutic agents to lower lipoprotein (a) levels. Curr Opin Lipidol. 2012; 23: 560-568. doi: 10.1097/MOL.0b013e3283598d81
52. Miller YI, Tsimikas S. Oxidation-specific epitopes as targets for biotheranostic applications in humans: biomarkers, molecular imaging and therapeutics. Curr Opin Lipidol. 2013; 24: 426-437. doi: 10.1097/MOL.0b013e328364e85a
53. Tsimikas S, Miyanohara A, Hartvigsen K, Merki E, Shaw PX, Chou MY, Pattison J, Torzewski M, Sollors J, Friedmann T, Lai NC, Hammond HK, Getz GS, Reardon CA, Li AC, Banka CL, Witztum JL. Human oxidation-specific antibodies reduce foam cell formation and atherosclerosis progression. J Am Coll Cardiol. 2011; 58: 1715-1727. doi: 10.1016/j.jacc.2011.07.017
54. Gonen A, Hansen LF, Turner WW, Montano EN, Que X, Rafia A, Chou MY, Wiesner P, Tsiantoulas D, Corr M, VanNieuwenhze MS, Tsimikas S, Binder CJ, Witztum JL, Hartvigsen K. Atheroprotective immunization with malondialdehyde-modified LDL is hapten specific and dependent on advanced MDA adducts: implications for development of an atheroprotective vaccine. J Lipid Res. 2014; 55: 2137-2155. doi: 10.1194/jlr.M053256